BIONXT SIGNS CLINICAL STUDY AGREEMENT AND COMMENCES MANUFACTURE OF CLINICAL SAMPLES FOR STUDY OF TRANSDERMAL ROTIGOTINE PATCH FOR PARKINSON’S DISEASE
Mar 1, 2023
VANCOUVER, BC – March 1, 2023 ‐ BioNxt Solutions Inc. (“BioNxt” or the “Company”) (CSE: BNXT / OTC: BNXTF / FSE: BXT) is pleased to...